Screening for prostatic cancer and its evolution within Britain

Journal of Pathology

Volumn 197, Issue 2, 2002, Pages 139-142

  Parkinson, M C ^a   Bott, S R J ^b   Montironi, R ^c   Melia, J ^a  

^a INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Prostrate cancer; PSA; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; CANCER SCREENING; CONTROLLED STUDY; DECISION MAKING; EDITORIAL; HEALTH PROGRAM; HISTOPATHOLOGY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; UNITED KINGDOM; WORKLOAD;

GREAT BRITAIN; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036265804     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1088     Document Type: Editorial

References (41)

1. Detection of prostatic cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase
2. Acid phosphatase reappraised
3. The predictive value of prostatic acid phosphatase as a screening test for prostatic cancer
4. Serum acid phosphatase in screening for carcinoma of the prostate
5. Progress and problems in screening for carcinoma of prostate
6. International trends and patterns of prostate cancer incidence and mortality
7. How many, how old, how soon?
8. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicentre clinical trial of 6630 men
9. Pilot study of screening for prostate cancer
10. The Bristol prostate cancer pilot screening study - A 3 year follow-up
11. The results of 5 year early prostate cancer detection intervention
12. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
13. Prostatic cancer screening in the Tyrol, Austria: Experience and results
14. Three year results of the Finnish prostate cancer screening trial
15. Prostatic specific antigen: A decade of discovery - What we have learned and where we are going
16. Prostate cancer detection at low prostate specific antigen
17. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: Relation to biopsy strategy
18. Prostate-specific antigen testing for early diagnosis of prostate cancer
19. Pathologic features of prostate cancer found at population-based screening with a 4 year interval
20. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection
21. Screening and early hormone treatment of prostate cancer are accumulating strong evidence and support
22. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the federal state of Tyrol, Austria
23. Comment re: Screening and early treatment of prostate cancer are accumulating strong evidence and support
24. Comparison of trends in prostate cancer mortality in England and Wales and the USA
25. The case for prostate cancer screening
26. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening
27. Histopathological prostate cancer characteristics at radical prostatectomy after population based screening
28. Evaluation of the digital rectal examination as a screening test for prostate cancer
29. The diagnosis, management, treatment and costs of prostate cancer in England and Wales
30. Diagnosis, management and screening of early localised prostate cancer
31. kip1, MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer
32. Screening for prostate cancer in the UK
33. Hereditary prostate cancer: Epidemiologic and clinical features
34. Cancer mortality in Africa and Caribbean migrants to England and Wales
35. Screening for prostate cancer: Evidence and perspectives
36. Survey of the rate of PSA testing in general practice
37. Have we begun prostate cancer screening in the community? Current concepts of PSA estimation and diagnosis of prostate cancer in an East London general practice
38. Small focus prostatic adenocarcinoma on biopsy: Incidence and significance
39. Changes in diagnosis of prostate needle biopsies: Comparison of the 1970s with 1999